Part 2
For nearly a decade,
I LISTENED AND LEARNED.
In sales and marketing meetings.
In waiting rooms.
In medical luncheons and lectures.
In adult and pediatric doctor’s offices.
In patient groups.
In mental health facilities.
In research hospitals.
In acute psychiatric situations.
In pharmacies.
In fund-raising events.
In storage facilities with FDA agents counting my samples.
In conversations with the insane.
In conversations with those who treat the depressed, unstable, and insane.
In patient advocate meetings.
In state-funded clinics where the cheapest drugs are injected into the most severe of patients.
In private-practice psychiatric offices in affluent cities.
In rural trailers turned into psychiatric offices with criminal police escorts for violent criminals.
In parking lots in a company car with a trunkful of samples to give away.
BUSINESS WAS BOOMING!
And I thought it was busy back then.
Sadly, the mental health crisis continues to grow, and in 2025, it’s projected that the pharmaceutical market for mental health could reach exponential growth from anxiety and depression, alone.
Add on other psychiatric and neurological disorders like increasing diagnoses of Alzheimer’s, Parkinson’s, Multiple Sclerosis, Autism, mood disorders, and other neuropsychiatric conditions, and you have to ask:
WHY IS THIS HAPPENING?
I’d love to know your thoughts.
